A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria

* Patients must have biopsy-proven AIDS-associated Kaposi's sarcoma.
* Evidence of HIV infection as manifested by a positive antibody test.

Exclusion Criteria

* Active drug or alcohol abuse.

Co-existing Condition:

Excluded are patients with:

* Active opportunistic infections requiring ongoing therapy.
* Excluded within 90 days of study entry:
* Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.
* Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
* Concurrent neoplasms other than basal cell carcinoma of the skin.
* Known hypersensitivity to polymycin B or neomycin.

Excluded are patients with:

* Active opportunistic infections requiring ongoing therapy.
* Excluded within 90 days of study entry:
* Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.
* Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
* Concurrent neoplasms other than basal cell carcinoma of the skin.
* Known hypersensitivity to polymycin B or neomycin.

Prior Medication:

Excluded:

* Interferon.
* Zidovudine (AZT).
* Excluded within 30 days of study entry:
* Any biologic modifiers, corticosteroids, cytotoxic chemotherapeutic agents.
* Other drugs which can cause neutropenia or significant nephrotoxicity.
* Rifampin or rifampin derivatives, or systemic anti-infectives.
* Excluded within 90 days of study entry:
* Other antiviral agents.
* A history of Pneumocystis carinii pneumonia (PCP) completed treatment.

Prior Treatment:

Excluded within 30 days of study entry:

* Radiation therapy.